BioMidwest

Found 69,311 articles

• Medexus Submits Application to List on the NasdaqManagement to host investor update webinar on January 25th at 2pm Eastern

  1/21/2021

  Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)   announced today that it has submitted its application to list on The Nasdaq Capital Market® (the “ Nasdaq ”). Ken d’Entremont, Chief Executive Officer of Medexus, commented, “The submission of our application to list on the Nasdaq marks a significant milestone for Medexus.

• Predictive Oncology Announces Closing of $2.2 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  1/21/2021

  Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 2,200,000 shares of its common stock

• Conformis, Inc. and SITES Medical Announce Development & Supply Agreement

  1/21/2021

  Conformis, Inc. (NASDAQ:CFMS) and SITES Medical, a firm dedicated to inventing and de-risking new orthopedic medical device technologies, today announced they have entered into a non-exclusive development and supply agreement. The companies will work together to incorporate SITES Medical’s proprietary OsteoSync Ti Technology into future Conformis’ cementless total knee replacement products. “We are excited to be part

• Civica to Build an Essential Medicines Manufacturing Facility in Virginia

  1/21/2021

  The new facility, part of a partnership with Virginia-based Phlow Corp., will employ more than 180 people and will help ensure a safe, stable, and affordable supply of essential generic medicines for U.S. patients

• Internationally Recognized Parathyroid Surgeons Join Tampa General Hospital

  1/21/2021

  Dr. Douglas E. Politz and Dr. José A. Lopez bring a combined 25 years of global expertise in parathyroid disease.

• Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents

  1/21/2021

  Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced

• Protech Home Medical Announces Date and Time for Q4 and Full Year Fiscal 2020 Conference Call and Audio Webcast

  1/21/2021

  Protech Home Medical Corp. (the “Company”) (TSXV: PTQ) (OTCQX: PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, today announced that it will host its Q4 and Full Year Fiscal 2020 earnings conference call and audio webcast on Friday, January 29, 2021 at 10:00 a.m. (EST).

• Baxter to Present at SVB Leerink 10th Annual Global Healthcare Conference

  1/21/2021

  Baxter International Inc. (NYSE:BAX), a will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time.

• Align Technology Establishes New Global Corporate Headquarters in Tempe, ArizonaSan Jose, California Campus Becomes West Coast Regional Headquarters and New Digital Innovation Center

  1/20/2021

  Align Technology, Inc. announced that it established its new global corporate headquarters in Tempe, Arizona, effective January 1, 2021.

• Tampa General Hospital Among the First in Nation to Participate in Study of New Investigative Device Designed to Destroy Tumors without Surgery

  1/20/2021

  Tampa General is one of the first sites in the nation to study the safety and efficacy of the device, which aims to use focused ultrasound to destroy tumors in the liver

• Aerobiotix, Inc. Announces Strategic Partnership with APIC

  1/20/2021

  Aerobiotix today announced a strategic partnership with the Association for Professionals in Infection Control and Epidemiology ( APIC ), the largest association for infection prevention and control (IPC) professionals. Since 2018, Aerobiotix has been a Strategic Partner and has again signed on as a 2021 APIC Strategic Partner.

• Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase

  1/20/2021

  Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that results from its ORION-1 (NCT03960866) Phase 2 clinical trial evaluating the safety and efficacy of Nyxol

• Abbott Receives Expanded Medicare Reimbursement for First-Of-Its-Kind MitraClip™ Device

  1/20/2021

   Abbott (NYSE: ABT) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) revised its National Coverage Determination (NCD) to expand coverage for transcatheter edge-to-edge repair (TEER), also referred to as transcatheter mitral valve repair (TMVr), to include patients with secondary (or functional) mitral regurgitation (MR) resulting from heart failure.

• UnitedHealth Group Reports Fourth Quarter and Full Year 2020 Results

  1/20/2021

  Fundamental execution was strong across UnitedHealth Group in the fourth quarter and throughout the full year 2020, led by Optum and by UnitedHealthcare’s community and senior benefit businesses, even as the Company delivered expansive voluntary relief efforts for consumers, care providers and customers across the health system.

• Akron Biotech Signs Exclusive Global Agreement with Octapharma to Produce Virally Inactivated Human AB Serum Derived from Octaplas® for the Cell Therapy Market

  1/20/2021

  Akron Biotechnology, LLC, announced it has signed an exclusive global agreement to manufacture virally inactivated Human AB Serum for the cell therapy market using Octaplas®, Octapharma’s pooled, solvent-detergent treated human plasma.

• Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2020 Financial Results on February 23, 2021

  1/20/2021

  Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the fourth quarter and year ended December 31, 2020 after the close of trading on Tuesday, February 23.   Inspire’s management team will host a corresponding conference

• 

  2021 Biopharma Update on the Novel Coronavirus: January 19

  1/19/2021

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 19, 2021.

• Centene Launches Youth Impact Award for Vaping Prevention

  1/19/2021

  Youth contest developed by the Centene Institute for Advanced Health Education™ empowers students to take action and inform peers about the dangers of vaping and e-cigarettes

• IDT Developing PrimeTime™ SARS-CoV-2/Flu Test for Comprehensive Patient Testing

  1/19/2021

  integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, is developing a multiplex RT-qPCR test that can detect and distinguish between SARS-CoV-2, influenza A, and influenza B from a single patient sample

• UMF Corporation Announces Laboratory Results Showing its Micrillon® Yarns Inactivate Human Coronavirus and Human Influenza A H1N1, and Destroy MRSA and E. coli

  1/19/2021

  UMF Corporation today announced that testing from award-winning contract research organization Integrated Pharma Services confirms that UMF's Micrillon® sheath and core fiber demonstrates significant antiviral properties against Human Coronavirus, which causes COVID-19, and Human Influenza A H1N1 virus in just minutes